Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0773 · 2 trials · 2 indications
BLP measurements were obtained with the participant sitting on the BLP exercise machine with flexed hips and knees. The participant held the handgrips with hips flexion and knees bent at a 90 degree angle and feet placed evenly on the footpad with heels placed approximately shoulder width apart. Participants were asked to slowly push the footpad forward, while keeping the knees slightly flexed, and bend back again slowly for one repetition. The BLP procedure measures the maximum amount of weight that the patient can push through his or her full range of motion one time.
| Arm | Type | Description |
|---|---|---|
| MK-0773 | EXPERIMENTAL | MK-0773 |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Postmenopausal Women- Active Agent Group | EXPERIMENTAL | - |
| Postmenopausal Women- Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Comparator: MK-0773 | DRUG | MK-0773 50 mg tablets twice daily, 6 month treatment period |
| Comparator: Placebo | DRUG | Placebo tablets twice daily, 6 month treatment period |
| MK 0773 | DRUG | 25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks |
| Placebo | DRUG | Placebo oral tablet b.i.d for 12 weeks |
Inclusion Criteria: * Patient is a woman who is 65 years of age or older * Patient's lean body mass is at least 1 standard deviation below the mean of a healthy young adult population * Patient has difficulty climbing 10 steps or walking outside on level ground for 1/4 mile without resting or Activ...
MK0773 is an investigational small molecule developed by Merck & Company, Inc. for endocrine-related conditions. It has been studied in clinical trials for osteoporosis and sarcopenia, which is the loss of muscle mass. MK0773 is not approved and remains in clinical development.
MK0773 has been studied for the treatment of osteoporosis and sarcopenia. Osteoporosis is a condition characterized by weakened bones, while sarcopenia refers to the loss of muscle mass. Both indications were evaluated in clinical trials, but MK0773 is not approved for any use.
MK0773 is developed by Merck & Company, Inc., which trades under the ticker symbol MRK. Merck is the sponsor of the clinical trials evaluating MK0773 in osteoporosis and sarcopenia.
MK0773 is in Phase 1 clinical development. One Phase 1 trial has been completed, and a Phase 2 trial in sarcopenia has also been completed. The drug is investigational and has not been approved by the FDA.
MK0773 has been evaluated in two completed clinical trials. NCT01011725 was a Phase 1 study of safety, tolerability, and efficacy in healthy postmenopausal women with osteoporosis. NCT00529659 was a Phase 2 study of safety and efficacy in women with sarcopenia.
Yes, MK0773 is the same as MK 0773. The alternative spelling with a space is sometimes used in study titles and references, such as Comparator: MK-0773. Both names refer to the same investigational drug developed by Merck.